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You should be able to safely assume that your doctor’s recommendations are evidence-based 
and in your best interests rather than driven by advertising. And this is precisely why we 
should be concerned about the plethora of drug company paraphernalia scattered around 
doctors' waiting and consultation rooms, surgeries, kitchens and elsewhere. 
It’s obvious why we worry about overtly manipulative practices, such as companies paying 
for overseas trips for doctors and their families, and providing other forms of lavish 
entertainment. This kind of generosity is likely to make doctors feel indebted to these 
companies and more likely to prescribe their products. 
But while such practices attract critical media attention, they’re not the most common, and, 
indeed, might not be the most effective form of pharmaceutical marketing. Even small 
“gifts”, such as the ubiquitous post-it note or pen bearing a medicine’s name, or a free sample 
of a drug, have the potential to influence doctors. The effect is that you are prescribed 
medicines that are either not needed or are more expensive than alternatives. 
This might seem surprising. After all, doctors are highly-educated, highly-trained 
professionals who undoubtedly have their patients’ best interests at heart. But they are also 
human, and even small gifts have the potential to create an unconscious desire to reciprocate 
by prescribing a company’s product. 
Indeed, small gifts can be even more influential than large gifts, because – precisely as a 
result of their small value – they operate insidiously, with doctors usually remaining unaware 
of their ability to influence their behaviour. 
What’s more, because of their conspicuous nature, small gifts are often more likely than 
larger ones to demean the profession by producing the appearance of bias or conflict of 
interest, even where none exists. 
While it’s difficult to prove that patients are actually disadvantaged by such gift-giving, the 
mere possibility of harm is sufficient justification to curtail a clearly unnecessary practice. 
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This is not to oppose all marketing activities, which – at least in principle – have the capacity 
to provide useful information to prescribers. 
Many professional organisations have taken steps — together with Medicines Australia (the 
pharmaceutical industry’s peak body) — to limit gift giving. Gifts of stationery branded with 
specific drug names, for instance, are no longer recommended by Medicines Australia. The 
Australian Medical Association (AMA) and professional colleges, such as the Royal 
Australasian College of Physicians, also have codes of ethics outlining acceptable behaviour 
with respect to interactions with industry. 
But while the pharmaceutical industry and the medical profession have incrementally 
increased restrictions on pharmaceutical marketing, both continue to accept extensive contact, 
and what constitutes acceptable behaviour remains highly subjective. They still allow for the 
continuation of other inappropriate practices, such as product brand name reminders on 
medical equipment, company-branded items of stationery and various kinds of support for 
education – as long as these are not deemed “excessive”. 
So why isn’t the community deeply concerned? Partly because the medical profession is so 
trusted that its activities are rarely questioned; partly because many of these interactions don’t 
occur in the public eye and partly because the lay and medical communities don’t feel the 
effects of pharmaceutical marketing. 
This latter is due to the fact that the Australian Pharmaceutical Benefits Scheme (PBS) 
provides generous subsidies for many expensive medicines. Patients need only contribute the 
“co-payment” which, at present, is capped at $35.40 for most PBS-listed medicines, and 
$5.80 if patients have a concession card or reach the safety net. 
As taxpayers, we all foot the bill for excessive or inappropriate prescribing. The PBS cost 
$7,679.3 million in the 2009 financial year, and over the ten years to 2004–05, this cost grew 
by nearly 13% each year. 
Every dollar spent on an unnecessary (or unnecessarily expensive) medicine is a dollar that 
can’t be spent on something else. Ultimately, gifts provided to doctors are not paid for by 
drug companies, but by patients, insurers, and the government. In other words, these costs are 
borne by us. So let’s face it, doctors don’t need pensioners to buy them free pens. 
